SCHEMBL4608702

SCHEMBL4608702

CCCCCCCCC(NC(=O)c1ccccc1O)C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 1/20 0.58
ALDH1A1 P00352 3/20 0.53
KDM4E B2RXH2 2/20 0.53
LMNA P02545 2/20 0.53
HPGD P15428 2/20 0.53
HSD17B10 Q99714 2/20 0.53
TSHR P16473 1/20 0.53
PYGL P06737 2/20 0.51
CA2 P00918 1/20 0.50
FOLH1 Q04609 3/20 0.48
FNTA P49354 1/20 0.47
FNTB P49356 1/20 0.47
CYP2C9 P11712 1/20 0.47
NOD1 Q9Y239 1/20 0.46
MME P08473 1/20 0.45
MET P08581 1/20 0.45
AGTR1 P30556 1/20 0.45
AGTR2 P50052 1/20 0.45
SIRT2 Q8IXJ6 1/20 0.45
SIRT1 Q96EB6 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4586238 1.00 NAAA (0.58) NAAAALDH1A1KDM4ELMNAHPGD
SCHEMBL6384132 0.99 NAAA (0.56) NAAAALDH1A1KDM4ELMNAHPGD
SCHEMBL29022047 0.85 ALOX5 (0.50) ALDH1A1KDM4ELMNAHPGDHSD17B10
SCHEMBL8670657 0.85 CA2 (0.54) NAAAALDH1A1KDM4ELMNAHPGD
SCHEMBL21579700 0.85 CA2 (0.54) NAAAALDH1A1KDM4ELMNAHPGD
SCHEMBL13892898 0.84 NAAA (0.61) NAAAALDH1A1KDM4ELMNAHPGD
SCHEMBL12300831 0.84 NAAA (0.60) NAAAPYGLCA2FOLH1CYP2C9
SCHEMBL7759090 0.83 CA2 (0.61) NAAAALDH1A1LMNAHSD17B10TSHR
SCHEMBL29036089 0.83 CA2 (0.61) NAAAALDH1A1LMNAHSD17B10TSHR
SCHEMBL5803352 0.83 KDM4E (0.66) NAAAALDH1A1KDM4ELMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1149066-B1 METHOD OF PREPARING ALKYLATED SALICYLAMIDES EMISPHERE TECH INC (US) 2005-11-09 EP claimed
EP-3256114-A1 TREATMENT OF OSTEOPOROSIS Entera Bio Ltd. (IL) 2017-12-20 EP disclosed
US-20170165369-A1 METHOD OF TREATING CANCER INTENSITY THERAPEUTICS, INC. 2017-06-15 US disclosed
WO-2016128973-A1 TREATMENT OF OSTEOPOROSIS ENTERA BIO LTD. (IL) 2016-08-18 WO disclosed
CN-102369018-B Treatment of diabetes and metabolic syndrome 关键生物科学有限公司 2016-08-03 CN disclosed
EP-1945243-A1 USE OF CALCITONIN FOR THE TREATMENT OF RA Novartis AG (CH) 2008-07-23 EP disclosed
WO-2007051641-A1 USE OF CALCITONIN FOR THE TREATMENT OF RA NOVARTIS AG (CH) 2007-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170165369-A1 METHOD OF TREATING CANCER PBK, GZMB, NPC1L1 NAAA 1268/4885ALDH1A1 3990/4885KDM4E 1887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.